sutimlimab-jome (Enjaymo)

Indications

• treatment of adults with cold agglutinin disease

Dosage

• weight-based dosage weekly for two weeks then every two weeks
• 39-75 kg: 6500 mg IV infusion
• > 75 mg: 7500 mg IV infusion
• vaccinate against encapsulated bacteria at least two weeks prior to treatment

Injection: 1,100 mg/22 mL (50 mg/mL) in a single-dose vial

Adverse effects

• > 10%
  • respiratory tract infection, viral infection, diarrhea, dyspepsia, cough, arthralgia, arthritis, peripheral edema

• drug adverse effects of pharmaceutical monoclonal antibodies

Mechanism of action

• classical complement inhibitor decreases need RBC transfusion due to hemolysis in adults with cold agglutinin disease

More general terms

• pharmaceutical monoclonal antibody
• hematologic agent